Inqovi (Decitabine)

Brand Name

Inqovi

Generic Name

Decitabine

View Brand Information

FDA approval date: July 11, 2013

Classification: Nucleoside Metabolic Inhibitor

Form: Injection, Tablet, Kit

What is Inqovi (Decitabine)?

INQOVI is a combination of decitabine, a nucleoside metabolic inhibitor, and cedazuridine, a cytidine deaminase inhibitor, indicated: For treatment of adult patients with myelodysplastic syndromes , including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia ) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups.

Approved To Treat

Top Global Experts

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Related Clinical Trials

A Phase 1 Study of Oral Cedazuridine and Decitabine Combination (ASTX727, NSC# 820631) and Filgrastim as Maintenance Therapy Post-Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

Enrollment Status: Recruiting

Publish Date: June 18, 2026

Intervention Type: Procedure, Drug, Biological

Study Phase: Phase 1

Summary: This phase I trial tests the safety, side effects, and best dose of ASTX727 and filgrastim for the treatment of children with high risk acute myeloid leukemia that has come back after a period of improvement (recurrent) or that does not respond to treatment (refractory) who have undergone allogenic hematopoietic stem cell transplantation. ASTX727 is a combination of cedazuridine and decitabine. Ce...

Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials

Enrollment Status: Recruiting

Publish Date: June 18, 2026

Intervention Type: Procedure, Drug, Biological, Other, Radiation

Study Phase: Phase 2

Summary: This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myeloid cancer (acute myeloid leukemia or myelodysplastic syndrome) treatment. This study involves testing patients' bone marrow and blood for certain biomarkers. A b...

Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies

Enrollment Status: Recruiting

Publish Date: June 12, 2026

Intervention Type: Drug

Study Phase: Phase 1/Phase 2

Summary: To find a recommended dose of PRAME-TCR-NK cells that can be given to patients with AML or MDS.

View All Clinical Trials